International Journal of Surgical Oncology / 2019 / Article / Tab 1

Review Article

A Concise Review of Pelvic Radiation Therapy (RT) for Rectal Cancer with Synchronous Liver Metastases

Table 1

Selected series incorporating pelvic RT in multimodality management of stage IV rectal cancer with liver metastases (with or without other distant metastases) as a palliative therapeutic strategy.

Authors (Reference)Study yearStudy designNumber of patientsDisease statusRT dose and fractionationMedian follow-up (range)Response to palliative RT

Crane et al. [85]2001Retrospective80Stage IV rectal cancer with synchronous distant metastases30 Gy/6 fx (50%)
45 Gy/25 fx (16%)
35 Gy/14 fx (14%)
Other (20%)
52 (3-444) weeksSymptoms due to rectal tumor resolved in 94%
Overall 1-year actuarial symptom control rate 85%
Overall 2-year actuarial symptom control rate 82%
Bae et al. [86]2011Retrospective80Metastatic stage IV colorectal cancerMedian total RT dose 36 Gy (range: 8-60 Gy)
Median dose per fraction 2.5 Gy (range: 1.8-8 Gy)
5 (1-44) monthsOverall symptomatic palliation rate 80%
Median symptom control duration 5 months (range: 1-44 months)
Tyc-Szczepaniak et al. [87]2013Prospective phase II study40Stage IV rectal cancer with synchronous distant metastases25 Gy/5 fx (97.5%)
30 Gy/6 fx (2.5%)
26 (19-34) monthsComplete resolution of pelvic symptoms during the whole course of disease in 12 patients (30%)
Significant improvement in 14 patients (35%)
67% probability of a sustained good palliative effect at 2 years
Picardi et al. [72]2016Prospective phase II study18Stage IV rectal cancer with synchronous distant metastases25 Gy/5 fx11.5 (3-36) monthsComplete response (i.e., complete resolution of symptoms) at 4 weeks after treatment in 7 patients (38.9%)
Partial response at 4 weeks after treatment in 9 patients (50%)
Reduction or resolution of pain 87.5%
Reduction or resolution of bleeding 100%

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.